Matthew Schofield

Phoqus Pharmaceuticals Plc develops pharmaceutical products. It's product Chronocort that helps to treat the patients with cortisol deficiency such as congenital adrenal hyperplasia and Addison's diseases. The company was founded in 1998 and is located in West Malling, UK.

Capricorn Partners NV (Capricorn) is an independent European licensed manager of private and public equity investment funds which was founded in 1993 as a joint venture between Dr Jos B. Peeters and Baring Venture Partners Ltd. In 1999, Capricorn became a fully partner-owned, independent firm. It is headquartered in Leuven, Belgium.

Oxford Gene Technology Ltd. develops arrays used in genomics research. It engages in providing services to the pharmaceutical and other sectors in making DNA arrays known as in-situ synthesis of oligonucleotide robes. The company was founded by Edwin Southern in 1995 and is headquartered in Begbroke, the United Kingdom.

Arrow Therapeutics Ltd. operates as a pharmaceutical company that focuses on research and development of novel antiviral drugs. Its products include novel antibacterial, antiviral, antifungal and preclinical compounds. The company was founded in 1998 and is headquartered in Cambridge, the United Kingdom.

Galapagos Biotech Ltd. operates as a drug discovery company which provides discovery technologies and services. Its technologies include Chemogenomics and Silico. The company was founded by Kenneth Leslie Powell and Janet Maureen Thornton in July 8, 1997 and is headquartered in Cambridge, the United Kingdom.

Ionix Pharmaceuticals Ltd. used to develop analgesic medicines for the treatment of acute and chronic pain. Its drugs were used for the treatment of pain associated with chronic debilitating diseases such as osteoarthritis, diabetes, cancer and multiple sclerosis. The company was founded by Andrew Sandham, Phillip J. Birch, John Wood and Ann Gail Hayes in 2001 and was located in Cambridge, UK.

Informa Connect Ltd. provides professional and technical solutions and services. It provides market conferences and training courses in sectors including accounting, fund management, and alternative investment. The company was founded in 1973 and is headquartered in London, the United Kingdom.

Avantium Technologies BV operates as chemical technology company. It offers a breeding ground for revolutionary renewable chemistry solutions. The firm specializes in innovations and technologies for catalytic research and development services and systems. The company was founded in February 2000 and is headquartered in Amsterdam, the Netherlands

GE Healthcare Ltd. provides transformational medical technologies and services which include icenter, AssetPlus, preventive maintenance, continuity, digital solutions and Unisys multi brand probe repair services. The firm offers magnetic resonance imaging, hemodynamic recording, EP recording, metabolic health and computed tomography. The company was founded on February 16, 1971 and is headquartered in Little Chalfont, the United Kingdom.

Oxford Drug Design Ltd. develops application of new technologies to drive computer-aided drug discovery. It specializes in drug discovery, molecular modeling, lead identification and optimisation, formulation modeling and preclinical studies. The company was founded by W. Graham Richards in 2001 and is headquartered in Oxford, the United Kingdom.

Part of Evotec SE, ProPharma Ltd. engages in pharmaceutical research and manufactures clinical trial supplies. The company is based in Glasgow, UK. ProPharma was acquired by Evotec SE from University of Strathclyde on October 25, 2005.

Keensight Capital SAS (Keensight) is an independent French venture capital firm which was established in 2001. Formerly known as R Capital Management SAS, a subsidiary of the Rothschild Group, the firm became independent in 2013 and changed their name to Keensight Capital. Keensight is located in Paris and manages venture capital investments, including the FCPR R Capital Technologies for a range of clients including European banks, pension schemes, insurance companies, government-controlled entities, fund of funds, family offices and high-net worth private individuals.

Prolysis Ltd. develops and manufactures pharmaceutical products. It develops antibacterial therapy to treat drug resistant infections. The company was founded in 1998 and is headquartered in Kidlington, UK.

Proimmune Ltd. develops, manufactures and distributes drugs. Its services include antigen characterization: T and B cell epitope discovery, immunogenicity risk management assays and cellular analysis services. The firm's products include pentamers, tetramers and monomers, CD1d tetramers, custom peptide products and antibodies. The company was founded by Linda Tan and Nikolai Schwabe in 2000 and is headquartered in Oxford, the United Kingdom.

CellCentric Ltd. develops and commercializes small molecule inhibitors for cancer. Its active programs include inhibitors to histone methyltransferases, histone demethylases and epigenetic enzymes that act via ubiquitin. The company was founded by Alun Huw Jones, Catherine Denise Prescott, Azim Surani and William Henry Lewarne West in May 2004 and is headquartered in Cambridge, the United Kingdom.

The BioIndustry Association is a UK-based organization that represents the life sciences and biotech industry. The British company's mission is to facilitate and connect the ecosystem to help businesses start, grow, and deliver world-changing innovation. The non-profit company was founded by Cormac G. Kilty and Simon Geoffrey Best, and Steve Bates has been the CEO of the company since 2012.

Capricorn Health-Tech Fund NV invests in companies located in Western Europe. It targets companies operating in the fields of human health-technology. It provides financing for seed stage, early stage and growth stage in equity and debt with an investment size between €0.5 million - €6 million. It acquires mostly minority stakes but also majority stakes.

European Biopharmaceutical Enterprises develops biological products. The private company is based in Brussels, Belgium.

Lontra Ltd. develops energy savings compressors and engines. It offers blade compressor, a rotary device with a wrapped toroidal chamber, and a compact and double acting rotary compressor for various industrial air markets, blowers, and specific process gas applications; and Blade supercharger, a displacement supercharger for heavily downsized gasoline and diesel powertrains. The company was founded by Stephen Francis Lindsey and Simon Hombersley in 2004 and is headquartered in Napton, the United Kingdom.

Synthace Ltd. produces bio-based chemical and biological products through synthetic biology. It is a synthetic biology company with a platform of technologies for the rapid engineering and optimization of novel biological production systems. The bioengineering platform is broadly applicable across multiple industry sectors, including the production of specialty chemicals from renewable feed stocks using efficient and sustainable processes. The company was founded by Sean Ward and Markus Christian Gershater in January 2011 and is headquartered in, London, the United Kingdom.

Achilles Therapeutics Ltd. operates as a biopharmaceutical company. The firm develops personalized vaccines and adoptive T cell therapies to treat metastatic cancer. It uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. The company was founded by Karl Peggs, Mark Lowdell, Charles Swanton and Sergio Quezada in May 2016 and is headquartered in London, the United Kingdom.

Labgenius Ltd. discovers novel and optimized biological molecules using artificial intelligence, automation and synthetic DNA. It specializes in synthetic biology, DNA libraries, protein engineering, artificial intelligence and machine learning. The company was founded by James Field in 2012 and is headquartered in London, the United Kingdom.

Evox Therapeutics Ltd. develops and markets transformational therapeutics. The firm creates novel exosome-based biotherapeutics for the treatment of various severe diseases with limited options for patients and their families. The company was founded by Matthew Wood, Per Lundin, and Samir EL Andaloussi in 2016 and is headquartered in Oxford, the United Kingdom.

Xampla Ltd. engages in the research, development, and creation of plant protein material that can be used commercially. The material performs like synthetic polymers, but decomposes naturally and fully, without harm to the environment. The company is headquartered in Cambridge, United Kingdom.

Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA.